Financial reports
10-Q
2015 Q3
Quarterly report
9 Nov 15
10-Q
2015 Q2
Quarterly report
14 Aug 15
10-Q
2015 Q1
Quarterly report
12 May 15
10-K
2014 FY
Annual report
3 Mar 15
10-Q
2014 Q3
Quarterly report
10 Nov 14
10-Q
2014 Q2
Quarterly report
11 Aug 14
10-Q
2014 Q1
Quarterly report
15 May 14
10-K
2013 FY
Annual report
31 Mar 14
10-Q
2013 Q3
Quarterly report
14 Nov 13
Current reports
8-K
Entry into a Material Definitive Agreement
11 Feb 16
8-K
Regulation FD Disclosure
5 Feb 16
8-K
Tribute Announces Results of Shareholder Vote
1 Feb 16
8-K
Leading Independent Advisors Recommend that Tribute Shareholders Vote FOR the Transaction
21 Jan 16
8-K
Tribute Mails Materials In Connection with Special Meeting of Shareholders to Approve Transaction with Pozen and Encourages Shareholders to Vote
11 Jan 16
8-K
Tribute Pharmaceuticals Receives Notice of Allowance for Canadian Patent Expanding Cambia® Use in Migraine Treatment
4 Jan 16
8-K
Regulation FD Disclosure
28 Dec 15
8-K
Regulation FD Disclosure
8 Dec 15
8-K/A
Financial Statements and Exhibits
2 Dec 15
8-K
Pozen and Tribute Provide Update on Pending Combination Transactions
23 Nov 15
Registration and prospectus
15-12G
Securities registration termination
12 Feb 16
D
$75M in debt / options / securities to be acquired, sold $75M, 3 investors
5 Feb 16
POS AM
Prospectus update (post-effective amendment)
5 Feb 16
POS AM
Prospectus update (post-effective amendment)
5 Feb 16
D
$75M in equity, sold $75M, 7 investors
5 Feb 16
POS AM
Prospectus update (post-effective amendment)
5 Feb 16
425
Business combination disclosure
6 Nov 15
D/A
$807.74K in options / securities to be acquired, 2 investors
10 Jun 15
D
$4.1M in equity, sold $4.1M, 2 investors
5 Jun 15
D
$6.58M in options / securities to be acquired, 13 investors
21 Oct 14
Proxies
DEF 14A
Definitive proxy
6 Jun 13
DEF 14A
Definitive proxy
1 Jun 11
DEF 14A
Definitive proxy
2 Jun 10
DEF 14A
Definitive proxy
21 May 09
DEF 14A
Definitive proxy
30 May 08
Other
UPLOAD
Letter from SEC
22 Mar 16
EFFECT
Notice of effectiveness
8 Feb 16
EFFECT
Notice of effectiveness
8 Feb 16
EFFECT
Notice of effectiveness
8 Feb 16
CT ORDER
Confidential treatment order
25 Sep 15
CT ORDER
Confidential treatment order
1 Sep 15
UPLOAD
Letter from SEC
27 Aug 15
UPLOAD
Letter from SEC
14 Aug 15
CT ORDER
Confidential treatment order
23 Jun 15
CT ORDER
Confidential treatment order
6 Feb 15
Ownership
SC 13G
Tribute Pharmaceuticals Canada Inc.
16 Feb 16
SC 13G/A
Tribute Pharmaceuticals Canada Inc.
10 Sep 15
SC 13G/A
Tribute Pharmaceuticals Canada Inc.
10 Jun 15
SC 13D
Tribute Pharmaceuticals Canada Inc.
24 Mar 15
SC 13D
Tribute Pharmaceuticals Canada Inc.
18 Mar 15
SC 13D/A
Tribute Pharmaceuticals Canada Inc.
16 Mar 15
SC 13D/A
Tribute Pharmaceuticals Canada Inc.
27 Feb 15
SC 13G/A
Tribute Pharmaceuticals Canada Inc.
13 Feb 15
SC 13G
Tribute Pharmaceuticals Canada Inc.
10 Oct 14
SC 13D/A
SJ STRATEGIC INVESTMENTS LLC
11 Mar 13